0       0

2018 Annual Sessions


OS36 - ORAL SESSION 36 - Antibodies and Rejection in Heart Transplantation: Donor Cells Tell No Lies


Apr 13, 2018 4:30pm ‐ Apr 13, 2018 6:00pm

Description

(359)  Donor-Derived Cell-Free DNA in D-OAR, a Real World, Clinical Use Heart Transplant Population
Jon Kobashigawa, MD

(252)  Donor-Specific Antibodies in Heart Transplantation: Do Clinicians Need to do Something Always?
Yasbanoo Moayedi, MD

(361)  The Evolving (In)significance of Panel Reactive Antibody on Cardiac Transplantation Outcomes in the Modern Era
Jennifer Chung, MD

(362)  Development of Rejection Risk Prediction Model by Routine Monitoring for De-novo Donor Specific Antibodies After Heart Transplantation
Ka Lam Wong, MBBS

(363)  Patients Bridged to Transplant with Durable LVAD Support Have a Higher Risk of Post-Transplant De Novo Donor Specific Antibodies
Robert Cole, MD

(364)  It’s HLA-DR Not HLA-DQ Donor-specific Antibody That is Correlated to CAV After Heart Transplant
Michael Olymbios, MD

Speaker(s):

Tags: NHSAH BSTR PATH HTX

You must be logged in and own this session in order to post comments.

Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content